Establishment Labs Holdings (NASDAQ: ESTA) reported Q4 EPS of $. Revenue for the quarter came in at $27 million versus the consensus estimate of $25.27 million.

Fourth Quarter Highlights and Outlook

• Fourth quarter worldwide sales of $27.0 million, an increase of 11% year-over-year and a new quarterly record; consistent with preannouncement on January 11, 2021
• 2021 guidance of $110 million to $112 million, an increase of 30% to 32% over 2020
• Fourth quarter operating expenses of $22.7 million, an increase of 9% compared to the fourth quarter of 2019
• Strong cash balance of $84.5 million as of December 31, 2020
• Updated 10-year Motiva post-market surveillance data on October 21, 2020 showing less than 1% complication rates in the key safety endpoints of capsular contracture and implant rupture in nearly 1.3 million implants placed worldwide outside of the United States
• Received CE mark for next generation Motiva Ergonomix2 silicone breast implant platform in December 2020; CE mark also includes the Motiva Ergonomix2 Diamond breast implant, a key component of the Motiva Mia system for minimally invasive breast enhancement
• Hosted virtual meeting on February 9, 2021 highlighting results from early patient case series with Motiva Mia, including procedure times as low as 13 minutes, fast recovery, low pain, and high patient satisfaction; also provided Establishment Labs’ initial market size estimate for Motiva Mia of 1.9 million procedures per year, translating to a total addressable market of $4-5 billion

“We delivered record fourth quarter revenue of $27.0 million, which was up 11% from the fourth quarter of 2019 and 18% from the third quarter of 2020,” said Juan José Chacón-Quirós, Chief Executive Officer. “With a strong recovery from the pandemic well underway and with continued momentum in our business in the first quarter, we are issuing full year 2021 revenue guidance of $110 million to $112 million, which is an annual growth rate of 30% to 32%.”

“Our singular focus on women’s health and the superior outcomes with our implants in the more than 80 countries in which we sell is resonating—and we continue to grow our total global market share.” Mr. Chacón-Quirós continued. “As we look to 2021 and beyond, our regulatory and commercial timelines to begin selling Motiva implants in the U.S. and Chinese markets are progressing as planned. We have also made significant progress in advancing our portfolio of differentiated technologies and offerings, including Ergonomix2, Motiva Mia, and Flora, our novel tissue expander. We believe we are on track not only to become the leader in breast aesthetics and reconstruction, but to expand these markets as we offer safe, differentiated and accessible solutions to women.”

GUIDANCE:

Establishment Labs Holdings sees FY2021 revenue of $110-112 million, versus the consensus of $109.48 million.

For earnings history and earnings-related data on Establishment Labs Holdings (ESTA) click here.